313 related articles for article (PubMed ID: 15390046)
41. Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications.
Hassin-Baer S; Cohen O; Vakil E; Sela BA; Nitsan Z; Schwartz R; Chapman J; Tanne D
Clin Neuropharmacol; 2006; 29(6):305-11. PubMed ID: 17095893
[TBL] [Abstract][Full Text] [Related]
42. Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens.
Mancini F; Comi C; Oggioni GD; Pacchetti C; Calandrella D; Coletti Moja M; Riboldazzi G; Tunesi S; Dal Fante M; Manfredi L; Lacerenza M; Cantello R; Antonini A
Parkinsonism Relat Disord; 2014 Jan; 20(1):27-31. PubMed ID: 24099722
[TBL] [Abstract][Full Text] [Related]
43. Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease.
dos Santos EF; Busanello EN; Miglioranza A; Zanatta A; Barchak AG; Vargas CR; Saute J; Rosa C; Carrion MJ; Camargo D; Dalbem A; da Costa JC; de Sousa Miguel SR; de Mello Rieder CR; Wajner M
Metab Brain Dis; 2009 Jun; 24(2):257-69. PubMed ID: 19294496
[TBL] [Abstract][Full Text] [Related]
44. Impaired transmethylation potential in Parkinson's disease patients treated with L-Dopa.
De Bonis ML; Tessitore A; Pellecchia MT; Longo K; Salvatore A; Russo A; Ingrosso D; Zappia V; Barone P; Galletti P; Tedeschi G
Neurosci Lett; 2010 Jan; 468(3):287-91. PubMed ID: 19909787
[TBL] [Abstract][Full Text] [Related]
45. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
[TBL] [Abstract][Full Text] [Related]
46. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease.
O'Suilleabhain PE; Bottiglieri T; Dewey RB; Sharma S; Diaz-Arrastia R
Mov Disord; 2004 Dec; 19(12):1403-8. PubMed ID: 15390053
[TBL] [Abstract][Full Text] [Related]
47. Peripheral COMT inhibition prevents levodopa associated homocysteine increase.
Müller T; Muhlack S
J Neural Transm (Vienna); 2009 Oct; 116(10):1253-6. PubMed ID: 19657587
[TBL] [Abstract][Full Text] [Related]
48. Methylenetetrahydrofolate reductase genotype, vitamin B12, and folate influence plasma homocysteine in hemodialysis patients.
Nakamura T; Saionji K; Hiejima Y; Hirayama H; Tago K; Takano H; Tajiri M; Hayashi K; Kawabata M; Funamizu M; Makita Y; Hata A
Am J Kidney Dis; 2002 May; 39(5):1032-9. PubMed ID: 11979347
[TBL] [Abstract][Full Text] [Related]
49. The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia.
Guo G; Xu S; Cao LD; Wu QY
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2409-12. PubMed ID: 27338068
[TBL] [Abstract][Full Text] [Related]
50. Association of homocysteine with ventricular dilatation and brain atrophy in Parkinson's disease.
Sapkota S; Gee M; Sabino J; Emery D; Camicioli R
Mov Disord; 2014 Mar; 29(3):368-74. PubMed ID: 24395213
[TBL] [Abstract][Full Text] [Related]
51. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
Ferreira JJ; Almeida L; Cunha L; Ticmeanu M; Rosa MM; Januário C; Mitu CE; Coelho M; Correia-Guedes L; Morgadinho A; Nunes T; Wright LC; Falcão A; Sampaio C; Soares-da-Silva P
Clin Neuropharmacol; 2008; 31(1):2-18. PubMed ID: 18303486
[TBL] [Abstract][Full Text] [Related]
52. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.
Müller T; Kolf K; Ander L; Woitalla D; Muhlack S
Clin Neuropharmacol; 2008; 31(3):134-40. PubMed ID: 18520980
[TBL] [Abstract][Full Text] [Related]
53. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations.
O'Suilleabhain PE; Sung V; Hernandez C; Lacritz L; Dewey RB; Bottiglieri T; Diaz-Arrastia R
Arch Neurol; 2004 Jun; 61(6):865-8. PubMed ID: 15210523
[TBL] [Abstract][Full Text] [Related]
54. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
Talati R; Reinhart K; Baker W; White CM; Coleman CI
Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
[TBL] [Abstract][Full Text] [Related]
55. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy.
Todorović Z; Dzoljić E; Novaković I; Mirković D; Stojanović R; Nesić Z; Krajinović M; Prostran M; Kostić V
J Neurol Sci; 2006 Oct; 248(1-2):56-61. PubMed ID: 16774768
[TBL] [Abstract][Full Text] [Related]
56. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
Miller JW; Selhub J; Nadeau MR; Thomas CA; Feldman RG; Wolf PA
Neurology; 2003 Apr; 60(7):1125-9. PubMed ID: 12682318
[TBL] [Abstract][Full Text] [Related]
57. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease.
Białecka M; Droździk M; Kłodowska-Duda G; Honczarenko K; Gawrońska-Szklarz B; Opala G; Stankiewicz J
Acta Neurol Scand; 2004 Oct; 110(4):260-6. PubMed ID: 15355491
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels.
Müller T; Erdmann C; Muhlack S; Bremen D; Przuntek H; Woitalla D
Mov Disord; 2006 Mar; 21(3):332-6. PubMed ID: 16211593
[TBL] [Abstract][Full Text] [Related]
59. Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson's disease.
Lee SH; Kim MJ; Kim BJ; Kim SR; Chun S; Kim HK; Ryu JS; Kim GS; Lee MC; Chung SJ; Koh JM
Calcif Tissue Int; 2010 Feb; 86(2):132-41. PubMed ID: 20049422
[TBL] [Abstract][Full Text] [Related]
60. Endothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: flow-mediated dilation study.
Yoon JH; Lee JS; Yong SW; Hong JM; Lee PH
Mov Disord; 2014 Oct; 29(12):1551-5. PubMed ID: 25154960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
